Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs ENTEREG
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.
Selective 5-HT4 receptor agonist; enhances gastrointestinal motility by increasing peristalsis and accelerating colonic transit.
Treatment of opioid dependence (FDA-approved),Maintenance therapy for opioid use disorder,Off-label: chronic pain management (limited use)
FDA-approved for the treatment of chronic idiopathic constipation in adults
Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.
Adults: 12 mg orally twice daily for up to 15 days, initiated within 30 minutes prior to surgery and continued postoperatively.
Buprenorphine: terminal half-life 24-60 hours (mean ~37h) due to slow dissociation from mu-opioid receptors; naloxone: ~2-12 hours (mean ~1-2h IV, slightly longer sublingual).
Terminal half-life is approximately 10–17 hours in healthy subjects. Clinically, the half-life may be prolonged in severe hepatic impairment but is not significantly altered in renal impairment.
Buprenorphine is primarily metabolized by CYP3A4 to norbuprenorphine; naloxone is metabolized by UDP-glucuronosyltransferases (UGT1A1, UGT1A3).
Primarily metabolized by cytochrome P450 3A4 (CYP3A4); also involves CYP2D6 and CYP2C9 to a lesser extent.
Buprenorphine: ~70% fecal via biliary excretion, ~30% renal as unchanged drug and metabolites. Naloxone: primarily hepatic metabolism, ~50% renal excretion of metabolites within 6h.
Primarily hepatobiliary excretion; unchanged drug and major metabolite (alvimopan) undergo extensive biliary elimination with fecal excretion accounting for >90% of total elimination. Renal excretion is minimal (<5% as unchanged drug).
Buprenorphine: ~96% bound to alpha- and beta-globulins; naloxone: ~45% bound to albumin (primarily).
Approximately 80–90% bound to plasma proteins, primarily albumin.
Buprenorphine: Vd ~2.5-4.0 L/kg (large distribution due to lipophilicity); naloxone: Vd ~2.0 L/kg.
Volume of distribution is about 30 L (approximately 0.4 L/kg), indicating distribution into extracellular fluid and tissues.
Sublingual buprenorphine: ~30-50% (avoid first-pass); sublingual naloxone: ~10% (low); IV: 100% both.
Oral bioavailability is approximately 6–10% due to extensive first-pass metabolism; the drug is administered orally for local gastrointestinal activity.
For GFR <30 m L/min: use with caution, dose reduction may be necessary; avoid in severe impairment (creatinine clearance <15 m L/min) due to naloxone accumulation.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) or dialysis.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce starting dose by 50%, monitor for oversedation. Child-Pugh Class C: not recommended.
No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Caution in severe hepatic impairment (Child-Pugh C); no specific dose recommendation.
Not approved for pediatric patients under 16 years for opioid use disorder; safety and efficacy not established.
Not FDA-approved for pediatric patients; safety and efficacy not established.
Initiate at lower end of dosing range (e.g., 2/0.5 mg sublingually once daily) due to increased sensitivity and potential for hepatic/renal impairment; titrate slowly and monitor for CNS depression.
No specific dose adjustment; use with caution due to potential increased sensitivity and renal function decline. Monitor for adverse effects.
Risk of respiratory depression, particularly in patients using other CNS depressants, and risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
No FDA boxed warning.
Respiratory depression risk with intravenous administration,Hepatotoxicity (elevated liver enzymes, hepatic failure),Adrenal insufficiency with chronic use,Interaction with benzodiazepines and other CNS depressants,Precipitation of withdrawal in opioid-dependent patients if administered too soon after last opioid use,Dependence and abuse potential (Schedule III controlled substance),Neonatal opioid withdrawal syndrome if used during pregnancy
May cause diarrhea, leading to electrolyte disturbances or hypovolemia,Use with caution in patients with severe renal impairment,Avoid use in patients with a history of mechanical gastrointestinal obstruction, perforation, or severe inflammatory bowel disease
Hypersensitivity to buprenorphine or naloxone,Severe respiratory insufficiency (e.g., acute asthma, COPD),Severe hepatic impairment,Patients with acute intoxication (alcohol, opioids, benzodiazepines),Concurrent use of MAO inhibitors (relative contraindication)
Hypersensitivity to prucalopride or any excipients,Renal impairment requiring dialysis,Intestinal obstruction or perforation
No significant food interactions; grapefruit juice may increase buprenorphine levels but not considered clinically relevant; alcohol is contraindicated due to additive CNS depression; take on an empty stomach or with food if GI upset occurs.
No specific food interactions reported. However, as ENTEREG is administered in a hospital setting, patients should follow the prescribed diet (typically clear liquids advancing to regular diet as tolerated postoperatively). Avoid grapefruit juice as it may affect drug metabolism via CYP3A4 (though not specifically studied, caution is advised).
Pregnancy category C: First trimester: Limited data; no clear evidence of major malformations, but opioid exposure may be associated with neural tube defects in some studies. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use. No known specific teratogenicity; however, maternal opioid use may lead to fetal growth restriction, preterm birth, and stillbirth. Buprenorphine/naloxone is preferred over methadone in pregnancy due to less neonatal respiratory depression and NOWS severity.
No human data; animal studies at doses up to 10 mg/kg/day in rats and rabbits showed no teratogenicity at exposures lower than human dose; risk cannot be excluded due to lack of adequate human studies.
Limited data; buprenorphine and naloxone are excreted into breast milk in low concentrations. The M/P ratio for buprenorphine is approximately 0.5–2.5, with high interindividual variability. Naloxone has poor oral bioavailability, reducing infant exposure. Benefits of breastfeeding likely outweigh risks if mother is stable on treatment. Monitor infant for sedation, respiratory depression, and adequate weight gain. Avoid use during breastfeeding in cases of high maternal doses or concurrent substance abuse.
No data on presence in human milk; caution advised; M/P ratio unknown.
Pregnancy may require dose increases due to increased plasma volume, enhanced clearance, and changes in protein binding. Buprenorphine is extensively metabolized by CYP3A4, which may be induced during pregnancy. Aim to maintain trough levels to prevent withdrawal. Usually, doses are adjusted based on clinical response (withdrawal symptoms, cravings). No fixed dose adjustment; individual titration is necessary. Higher doses (up to 50% increase) may be needed in late pregnancy. Postpartum, doses should be tapered back to prepregnancy levels gradually.
No pharmacokinetic studies in pregnancy; dose adjustment not required based on available data.
Avoid in patients with known respiratory insufficiency or acute opioid intoxication; use with caution in hepatic impairment; buprenorphine has a ceiling effect for respiratory depression; naloxone component prevents IV abuse; monitor for precipitated withdrawal if initiated too soon after last opioid use; requires at least 12 hours since last short-acting opioid or 24-72 hours for long-acting opioids; can cause QT prolongation at high doses; sublingual absorption is critical; consider dose adjustment in renal impairment.
ENTEREG (alvimopan) is a peripherally acting mu-opioid receptor antagonist indicated to accelerate postoperative recovery of GI function after bowel resection surgery. It does not cross the blood-brain barrier, so it does not reverse opioid analgesia. Use is restricted to hospitalized patients; it should not be used for more than 7 days. Contraindicated in patients who have taken therapeutic doses of opioids for >7 consecutive days immediately prior to initiation, as it may precipitate opioid withdrawal. Monitor for GI adverse effects such as nausea, vomiting, and abdominal pain.
Place the tablet/film under the tongue until fully dissolved; do not chew, swallow, or crush.,Do not use alcohol or other sedatives (benzodiazepines, muscle relaxants, sleeping pills) as this can cause severe respiratory depression or coma.,Keep out of reach of children and pets; accidental ingestion is life-threatening.,Avoid driving or operating machinery until you know how the medication affects you.,Do not stop suddenly; withdrawal symptoms can occur; taper under medical supervision.,Store at room temperature away from moisture and heat.,Tell all healthcare providers you are taking this medication before any surgery or new prescriptions.,Seek emergency help if you experience difficulty breathing, chest pain, or signs of allergic reaction (rash, swelling).,If you miss a dose, skip it; do not double dose.
Take ENTEREG exactly as prescribed; do not take more than the recommended dose.,This medication is used only in the hospital after bowel surgery to help your bowels start working again.,It does not reduce pain or interfere with your pain medication.,Report any severe abdominal pain, nausea, vomiting, or diarrhea to your healthcare provider.,Do not take this medication if you have recently taken opioid pain medications for more than 7 days in a row.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs ENTEREG, answered by our medical review team.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is a Opioid Antagonist that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.. ENTEREG is a Peripheral Opioid Antagonist that works by Selective 5-HT4 receptor agonist; enhances gastrointestinal motility by increasing peristalsis and accelerating colonic transit.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE and ENTEREG depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is: Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.. The standard adult dose of ENTEREG is: Adults: 12 mg orally twice daily for up to 15 days, initiated within 30 minutes prior to surgery and continued postoperatively.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE and ENTEREG in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is classified as Category A/B. Pregnancy category C: First trimester: Limited data; no clear evidence of major malformations, but opioid exposure may be associated with neural tube defects in some studies. Secon. ENTEREG is classified as Category C. No human data; animal studies at doses up to 10 mg/kg/day in rats and rabbits showed no teratogenicity at exposures lower than human dose; risk cannot be excluded due to lack of ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.